Kiniksa Pharmaceuticals International, plc (KNSA)

NMS – Real vaqt narxi. Valyuta: USD

59.48

+1.11 (1.90%)

Yopilishda: May 12, 2026, 4:00 PM EDT

59.65

+0.17 (0.29%)

Bozor oldidan: May 13, 2026, 7:17 AM EDT

29.04.2026

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.

28.04.2026

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.

28.04.2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

28.04.2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

28.04.2026

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

23.04.2026

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.

17.04.2026

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026. The director reported still holding 27,418 Class A ordinary shares after the transaction.

Videolar

No Data

There is no data to display

Press-relizlar

28.04.2026

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

08.04.2026

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by clicking on this link – LONDON, April 08, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced the launch of Heart's Home™, a Direct-to-Consumer (DTC) campaign for ARCALYST, the first-and-only U.S. Food and Drug Administration (FDA) approved therapy for recurrent pericarditis. This multi-faceted campaign is aimed at identifying, educating, and empowering patients living with recurrent pericarditis to discuss ARCALYST with their healthcare provider.

24.02.2026

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by the end of 2026 – – Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full year 2025 financial results and recent portfolio execution. “Kiniksa continued to drive significant advancements across its commercial and clinical portfolio in 2025.

12.01.2026

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by year end – – Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) –

Kiniksa Pharmaceuticals International, plc (KNSA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

Videolar

No Data

Press-relizlar

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Provides Corporate Update

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

Videolar

No Data

Press-relizlar

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Provides Corporate Update

Search stocks

Kiniksa Pharmaceuticals International, plc (KNSA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

Videolar

No Data

Press-relizlar

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Provides Corporate Update

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

Videolar

No Data

Press-relizlar

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Provides Corporate Update